Market Reports Center One Stop Market Research Shop COPD Drugs Market Share, Size, Price, Growth, Trends and Forecast 2016 – 2020 Technavio Announces the Publication of its Research Report – COPD Drugs Market in China 2016-2020 Technavio recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis. Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab. Download Brochure now @ https://marketreportscenter.com/reports/313820/copd-drugs-market-inchina-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “A key trend which is boosting market growth is the increased focus on combination therapies. Combination therapies have a better advantage over monotherapies in providing better efficacy in the treatment of a condition. Manufacturers are now concentrating on developing combination therapies to treat COPD.These combination therapies reduce COPD-related hospitalizations and bring out better treatment outcomes in patients. Thus, the development of combinations therapies will increase the patient compliance toward the uptake of medications and help in the growth of the market.” According to the report, pollutants such as ground-level ozone, carbon dioxide, smog, fumes from vehicles, and particulates such as dust, soot, and pollen grains are known to trigger diseases such as COPD, asthma, bronchitis, and other respiratory issues. Airborne particles, sulfur dioxide, and nitrogen oxide are critical environment pollutants that worsen respiratory symptoms. Rapid globalization, urbanization, and industrialization have led to the rise in environmental pollution, which has increased the prevalence of COPD. Further, the report states that a major factor that could hamper market growth is the low diagnosis rate of COPD. It is difficult for physicians to recognize COPD at an early stage as the first symptoms of the disease include common problems such as a cough, sputum production, and shortness of breath. Thus, the diagnosis rate is only about one-third of the prevalent cases. This low diagnosis of COPD can be attributed to the lack of physician’ s awareness about the risk factors, symptoms, and biomarkers of the disease. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated. The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region. Technavio’ s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product. The market is divided into the following segments based on drug class: • Bronchodilators • Phosphodiesterase-4 (PDE-4) inhibitors • Steroids • Combination therapies Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors • AstraZeneca • Boehringer Ingelheim • GSK • Merck • Novartis Other prominent vendors • Ache Laboratorios Farmaceuticos • Almirall • Aquinox Pharmaceuticals • Ario Pharma • BioMarck Pharmaceuticals • Gilead Sciences • Mereo BioPharma Group • Mylan • Orion • Pearl Therapeutics • Prosonix • Teva Pharmaceutical Industry • Theravance Biopharma • Theron Pharmaceuticals • Verona Pharma • Xention • ZAI Lab Market driver • Increase in environmental pollution • For a full, detailed list, view our report Market challenge • Low diagnosis rate • For a full, detailed list, view our report Market trend • Increased focus on combination therapies • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst’ s time when you purchase this market report. Details are provided within the report. Request for discount @ https://marketreportscenter.com/request-discount/313820 Table Of Content PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: COPD: An overview • Causes and risk factors • Symptoms • Diagnosis • Management PART 06: China-Country snapshot • Social and economic conditions • Healthcare reform • Healthcare infrastructure PART 07: Pharmaceutical industry in China • Market overview • Major pharmaceutical vendors in China • Opportunities for global and local vendors • Drug approval process in China PART 08: Drug pricing and reimbursement • Market-driven drug pricing strategy • Scrutinization of illegal pricing of drugs PART 09: Pipeline portfolio PART 10: Global respiratory drugs market • Market overview • Global COPD drugs market PART 11: Market landscape • COPD drugs market in china • Five forces analysis PART 12: Market segmentation by drug class • Bronchodilators • PDE-4 inhibitors • Steroids • Combination therapies • Other medications PART 13: Market drivers • Increase in prevalence of smoking • Rise in healthcare expenditure • Increase in environmental pollution PART 14: Impact of drivers To Get Request Sample for this Reports: https://marketreportscenter.com/request-sample/313820 For more information content with us; Sam Collins Market Reports Center 1-646-883-3044 (US) info@marketreportscenter.com https://marketreportscenter.com
Technavio recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis.
© Copyright 2024 Paperzz
